drugset / Trial / NCT03121846
Mesylate Apatinib for Stage Ⅳ STS After Failure of Chemotherapy
Phase 2
Unknown
80 enrolled
Tianjin Medical University Cancer Institute and Hospital
Fudan University · collabGansu Cancer Hospital · collabLiaoning Cancer Hospital & Institute · collabZhejiang Cancer Hospital · collab
NaSingle-groupOpen-labelTreatment
Summary
This is a Prospective, Open-label, Single-Arm, Multi-center phase II clinical trial evaluating the efficacy and safety of Apatinib for Chemotherapy Failure Ⅳ Stage Soft Tissue Sarcoma.
Timeline
- Start
- 2017-05-01
- Primary completion
- 2018-11-01
- Completion
- 2019-05-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Rivoceranib | Small molecule | 500 mg | Oral |